The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.
None
Histologically or cytologically diagnosed mixed small cell lung cancer or non-small cell lung cancer.
Extensive-stage small cell lung cancer.
Has malignant pleural or pericardial effusion.
Previously received systemic anti-tumor therapy for SCLC or anti-tumor therapy with immune checkpoint inhibitors.
Sun Yat-sen University
Lead sponsor